Aerion Bioscience’s Post

#𝐈𝐋𝟐 𝐢𝐬 𝐭𝐫𝐚𝐝𝐢𝐭𝐢𝐨𝐧𝐚𝐥𝐥𝐲 𝐤𝐧𝐨𝐰𝐧 𝐭𝐨 𝐞𝐧𝐡𝐚𝐧𝐜𝐞 #𝐞𝐟𝐟𝐞𝐜𝐭𝐨𝐫 #𝐓𝐜𝐞𝐥𝐥 𝐟𝐮𝐧𝐜𝐭𝐢𝐨𝐧 𝐛𝐮𝐭 𝐚𝐥𝐬𝐨 𝐜𝐚𝐧 𝐥𝐞𝐚𝐝 𝐭𝐨 #𝐭𝐨𝐱𝐢𝐜𝐢𝐭𝐲 𝐚𝐧𝐝 𝐢𝐦𝐦𝐮𝐧𝐨𝐬𝐮𝐩𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧. 𝐖𝐡𝐚𝐭 𝐢𝐟 𝐈𝐋𝟐 𝐜𝐚𝐧 𝐛𝐞 𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜𝐚𝐥𝐥𝐲 #𝐭𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐭𝐨 #𝐂𝐃𝟖 #𝐓𝐜𝐞𝐥𝐥𝐬? Researchers from The Netherlands Cancer Institute and Asher Biotherapeutics developed #CD8-targeted #IL2 #fusion molecule (CD8-IL2) to selectively reactivate intratumoral CD8 T cells and activate immune function. They also developed a molecule, AB248, a CD8 cis-targeted IL-2 that demonstrates over #500-#fold #preference for CD8 T cells over NK and Treg cells. Both the studies are published in Cancer Discovery, an American Association for Cancer Research journal. Congrats to the entire team led by Paulien Kaptein, Kelly Moynihan, Ivana Djuretic and Daniela Thommen. https://lnkd.in/gGKYyW48 https://lnkd.in/g6iJvrG6 https://lnkd.in/gemFND7x

IsoPSA has a specificity of two to three times that of traditional PSA tests. Unlike the PSA test, which measures the total amount of PSA protein circulating in the blood, IsoPSA can help identify certain types of PSA proteins that may have originated in cancer cells. IsoPSA provides greater clarity for ruling out risk of high-grade, aggressive cancer and can reduce unnecessary prostate biopsies by up to 55%. We take pride in being an integral part of the cancer diagnostics community and are dedicated to revolutionizing cancer diagnostics. https://bit.ly/3TLil4T #prostatecancer #cancerdiagnostics

June is Cancer Immunotherapy Month, spotlighting the innovative ways researchers are leveraging our immune system to combat cancer. At Sengenics, we’re proud to support this fight with advanced tools to measure autoantibody biomarkers. Explore how autoantibodies are advancing cancer precision medicine in our latest white paper: https://lnkd.in/emUfVvNf #CancerResearch #Biomarkers #PrecisionMedicine #DrugDevelopment #VaccineDevelopment #TherapeuticTargets

The Technion is breaking barriers when it comes to cancer therapies. By combining nanoscale gold particles and near-infrared light, the Light-Triggered Cancer Treatment provides precise, non-invasive drug delivery. Explore how medical innovations from a Technion - Israel Institute of Technology alumnus are changing the game in the world of cancer treatments. Download our Technion Booklet of Wonders https://bit.ly/45wDiFX.

🇳🇴 Norway's precision medicine revolution is taking the fight to cancer! Discover how biotech companies like Nykode Therapeutics are teaming up with global pharma to develop innovative cancer vaccines and therapies. The IMPRESS-Norway clinical trial is paving the way for improved public cancer care through precision medicine. Want to know more about Norway's thriving ecosystem and its impact on cancer treatment? Click to learn more👇 #PrecisionMedicine #CancerResearch #BiotechInnovation #NorwegianHealthcare #InvestInNorway

🚀 Overcoming Barriers in Lung Cancer Screening: Insights from Recent Research 🩺 Recent studies highlight critical barriers in lung cancer screening, such as socioeconomic factors and access to technology. Addressing these challenges is essential for early diagnosis and treatment. At The Behnke Group, we support Cizzle Bio, Inc.'s mission to improve lung cancer screening through the innovative CIZ1B biomarker test. This test aims to make screening more accessible and effective for everyone. 🔗 Read the full article to learn more: https://buff.ly/4cYBnNg #HealthcareInnovation #LungCancerAwareness #EarlyDetection #Biotechnology #CizzleBio

On World Lung Cancer Day, we stand with everyone affected by lung cancer, emphasizing the importance of research, early detection, and availability of novel treatments for better patient outcomes. We are investigating our hexavalent OX40 agonist, #INBRX106, in Non-Small Cell Lung Cancer (NSCLC) in our actively enrolling Phase 1 study. Inhibrx is committed to advancing research in lung cancer in the hopes of identifying potential new treatment options. Learn more about our actively enrolling clinical trial here: https://bit.ly/49ZyYks #Inhibrx #BioTechnology

Dana-Farber Cancer Institute researchers developed a 'G9' CAR, meticulously engineered to precisely target kidney cancer cells with exceptional specificity, binding with high Cell Avidity. By sparing healthy cells, this breakthrough significantly reduces the risk of adverse side effects in clinical settings. This milestone not only demonstrates the efficacy of the G9 CAR but also underscores the significance of evaluating cell-cell interactions using avidity metrics. Check out our latest Labiotech article here: https://bit.ly/3WQF4jg

Understanding Patient Barriers to Utilization of Low-dose CT Lung Cancer Screening in a High-risk Population 🔗 https://bit.ly/46qLZSV The purpose of this study was to assess factors that may affect low-dose CT (LDCT) utilization for lung cancer screening in a diverse population. The authors hypothesized that a lack of medical provider support may contribute to underutilization of LDCT for lung cancer screening.

Next week we’ll be attending #ASCO24 in Chicago. We’re looking forward to learning the latest advancements in cancer care and connecting with 40,000 oncology professionals from around the world. The theme for this year’s meeting is “The Art and Science of Cancer Care: From Comfort to Cure.” The sessions will also examine state-of-the-art approaches in disease sites and biologics in lung cancer and biomarkers. What are you most excited about at ASCO? Let us know in the comments! #lungcancer #innovation #cancerresearch #oncology #ASCOChicago #CIZ